Serum levels and urinary excretion of salusin-α in renal insufficiency

Regulatory Peptides

Volumn 162, Issue 1-3, 2010, Pages 129-132

  Kimoto, Shigeaki ^a   Sato, Kengo ^b   Watanabe, Takuya ^c   Suguro, Toshiaki ^c   Koyama, Takatoshi ^b   Shichiri, Masayoshi ^d  

^a Ohme Municipal General Hospital   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Chronic renal failure; EGFR; Fractional excretion; Radioimmunoassay; Salusin

Indexed keywords

PEPTIDE; SALUSIN ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; CAROTID ARTERIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; RENAL INSUFFICIENCY;

EID: 77952669439     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.03.009     Document Type: Article

References (23)

1. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266. K/DOQI.
2. Bayes B., Pastor M.C., Bonal J., Romero R. New cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment. Kidney Int 2005, S39-S43.
3. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
4. Izumiyama H., Tanaka H., Egi K., Sunamori M., Hirata Y., Shichiri M. Synthetic salusins as cardiac depressors in rat. Hypertension 2005, 45:419-425.
5. Marumo F., Shichiri M., Emori T., Ando K. Circulating and excreted forms of atrial natriuretic peptide in healthy subjects and patients with renal diseases. Clin Nephrol 1992, 38:203-208.
6. Matsuo S., Imai E., Horio M., Yasuda Y., Tomita K., Nitta K., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
7. Matsushita M., Shichiri M., Fukai N., Ozawa N., Yoshimoto T., Takasu N., et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology 2003, 144:1825-1831.
8. Nakayama C., Shichiri M., Sato K., Hirata Y. Expression of prosalusin in human neuroblastoma cells. Peptides 2009, 30:1362-1367.
9. Ogihara T., Kikuchi K., Matsuoka H., Fujita T., Higaki J., Horiuchi M., et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009, 32:3-107.
10. Ohta K., Hirata Y., Shichiri M., Kanno K., Emori T., Tomita K., et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991, 39:307-311.
11. i increase and neurohypophyseal hormone release from the axon terminals. J Neuroendocrinol 2008, 20:207-219.
12. Sato K., Fujimoto K., Koyama T., Shichiri M. Release of salusin-β from human monocytes/macrophages. Regul Pept 2010, 162:68-72.
13. Sato K., Koyama T., Shichiri M. Biosynthesis and secretion of salusin-α from human cells. Peptides 2008, 29:2203-2207.
14. Sato K., Koyama T., Tateno T., Hirata Y., Shichiri M. Presence of immunoreactive salusin-α in human serum and urine. Peptides 2006, 27:2561-2566.
15. Sato K., Sato T., Susumu T., Koyama T., Shichiri M. Presence of immunoreactive salusin-β in human plasma and urine. Regul Pept 2009, 158:63-67.
16. Shichiri M. Reply to 'Salusins; newly identified bioactive peptides with hemodynamic and mitogenic activities'. Nat Med 2007, 13:661-662.
17. Shichiri M., Hirata Y., Emori T., Ohta K., Nakajima T., Sato K., et al. Secretion of endothelin and related peptides from renal epithelial cell lines. FEBS Lett 1989, 253:203-206.
18. Shichiri M., Ishimaru S., Ota T., Nishikawa T., Isogai T., Hirata Y. Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med 2003, 9:1166-1172.
19. Takenoya F., Hori T., Kageyama H., Funahashi H., Takeuchi M., Kitamura Y., et al. Coexistence of salusin and vasopressin in the rat hypothalamo-hypophyseal system. Neurosci Lett 2005, 385:110-113.
20. Tonelli M., Wiebe N., Culleton B., House A., Rabbat C., Fok M., et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006, 17:2034-2047.
21. Watanabe T., Nishio K., Kanome T., Matsuyama T.A., Koba S., Sakai T., et al. Impact of salusin-α and -β on human macrophage foam cell formation and coronary atherosclerosis. Circulation 2008, 117:638-648.
22. Watanabe T., Suguro T., Sato K., Koyama T., Nagashima M., Kodate S., et al. Serum salusin-α levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens Res 2008, 31:463-468.
23. Yu F., Zhao J., Yang J., Gen B., Wang S., Feng X., et al. Salusins promote cardiomyocyte growth but does not affect cardiac function in rats. Regul Pept 2004, 122:191-197.